Complications of PORT-A-CATH® in patients with sickle cell disease

Summary: Background: Red cell exchange/transfusion is frequently used in the management of patients with medical complications related to acute severe sickle cell disease (SCD). However, peripheral venous access is often difficult without central venous catheters (CVCs) in adult patients with moder...

Full description

Bibliographic Details
Main Authors: Salam Alkindi, Samaa Matwani, Alghalia Al-Maawali, Buthaina Al-Maskari, Anil Pathare
Format: Article
Language:English
Published: Elsevier 2012-02-01
Series:Journal of Infection and Public Health
Online Access:http://www.sciencedirect.com/science/article/pii/S1876034111001055
id doaj-91c1af13ee234bb3a030c573c6550939
record_format Article
spelling doaj-91c1af13ee234bb3a030c573c65509392020-11-25T02:47:39ZengElsevierJournal of Infection and Public Health1876-03412012-02-01515762Complications of PORT-A-CATH® in patients with sickle cell diseaseSalam Alkindi0Samaa Matwani1Alghalia Al-Maawali2Buthaina Al-Maskari3Anil Pathare4Department of Hematology, College of Medicine & Health Sciences, Sultan Qaboos University Hospital, Oman; Corresponding author at: Department of Hematology, College of Medicine & Health Sciences, Sultan Qaboos University, P.O. Box 35, Muscat 123, Oman. Tel.: +968 24144947; fax: +968 24413419.College of Medicine & Health Sciences, Sultan Qaboos University, OmanCollege of Medicine & Health Sciences, Sultan Qaboos University, OmanCollege of Medicine & Health Sciences, Sultan Qaboos University, OmanDepartment of Hematology, Sultan Qaboos University Hospital, OmanSummary: Background: Red cell exchange/transfusion is frequently used in the management of patients with medical complications related to acute severe sickle cell disease (SCD). However, peripheral venous access is often difficult without central venous catheters (CVCs) in adult patients with moderate or severe SCD. Aims: To review our experience with the use of the PORT-A-CATH® device in sixteen patients with SCD undergoing exchange or simple transfusions. Methods: Among a cohort of 550 patients who frequently visited the inpatient service, sixteen SCD patients required the insertion of a PORT-A-CATH® device. These patients included 3 males and 13 females, aged 25–44 years [31.1 ± 2.3; mean ± SD]. A total of 24 PORT-A-CATH® devices were implanted in these 16 patients during the study period. Eleven patients had 1 device implanted, three patients had 2 devices, one patient had 3 devices, and one patient had 4 devices implanted. Results: Out of the 24 devices implanted, 17 required removal, due to either infection associated with sepsis and/or thrombosis. The organisms involved were Candida spp. (3), C. Parapsilosis (2), C. albicans (1), C. famata (1), C. lusitanice (1), Staphylococcus spp. (6), and S. aureus (3), as well as the coagulase-negative Staphylococcus (2), alpha hemolytic Streptococcus (1), Diphtheroid bacilli (2), Pseudomonas aeruginosa (2), Ps. Spp. (3), Escherichia coli (3), Klebsiella oxytoca (1), Klebsiella pneumoniae (1), Klebsiella spp. (1), Serratia liquefaciens (1), Serratia fanticola (1), Achromobacter spp. (2) Chromobacterium violaceum (1), Delftia acidovirans (1), Stenotrophomonas maltophile (1), Alcaligenes faecalis (1), and Enterobacter cloacae (1). Two episodes of documented thrombosis were observed. One case presented with right atrial thrombosis/SVC syndrome and the other case presented with left upper arm thrombosis. Two patients died with ports in situ, while five patients had ports in place at the time of this study. The median working life of the ports was 688.5 days (range: 39–3925). The rate of infective complications was 2.63 infections per 1000 catheter days, and the number of infections was significantly correlated with the number of ports [Pearson's r = 0.66; p < 0.01]. Discussion: Our results suggest that patients with SCD suffer infective complications associated with the PORT-A-CATH®, which often necessitate its removal. Although these devices are extremely useful, their optimal beneficial potential is only realized if the patients receive proper care at special centers well-versed in the maintenance of such devices by experienced staff. Keywords: PORT-A-CATH®, Sickle cell disease, Infections, Complicationshttp://www.sciencedirect.com/science/article/pii/S1876034111001055
collection DOAJ
language English
format Article
sources DOAJ
author Salam Alkindi
Samaa Matwani
Alghalia Al-Maawali
Buthaina Al-Maskari
Anil Pathare
spellingShingle Salam Alkindi
Samaa Matwani
Alghalia Al-Maawali
Buthaina Al-Maskari
Anil Pathare
Complications of PORT-A-CATH® in patients with sickle cell disease
Journal of Infection and Public Health
author_facet Salam Alkindi
Samaa Matwani
Alghalia Al-Maawali
Buthaina Al-Maskari
Anil Pathare
author_sort Salam Alkindi
title Complications of PORT-A-CATH® in patients with sickle cell disease
title_short Complications of PORT-A-CATH® in patients with sickle cell disease
title_full Complications of PORT-A-CATH® in patients with sickle cell disease
title_fullStr Complications of PORT-A-CATH® in patients with sickle cell disease
title_full_unstemmed Complications of PORT-A-CATH® in patients with sickle cell disease
title_sort complications of port-a-cath® in patients with sickle cell disease
publisher Elsevier
series Journal of Infection and Public Health
issn 1876-0341
publishDate 2012-02-01
description Summary: Background: Red cell exchange/transfusion is frequently used in the management of patients with medical complications related to acute severe sickle cell disease (SCD). However, peripheral venous access is often difficult without central venous catheters (CVCs) in adult patients with moderate or severe SCD. Aims: To review our experience with the use of the PORT-A-CATH® device in sixteen patients with SCD undergoing exchange or simple transfusions. Methods: Among a cohort of 550 patients who frequently visited the inpatient service, sixteen SCD patients required the insertion of a PORT-A-CATH® device. These patients included 3 males and 13 females, aged 25–44 years [31.1 ± 2.3; mean ± SD]. A total of 24 PORT-A-CATH® devices were implanted in these 16 patients during the study period. Eleven patients had 1 device implanted, three patients had 2 devices, one patient had 3 devices, and one patient had 4 devices implanted. Results: Out of the 24 devices implanted, 17 required removal, due to either infection associated with sepsis and/or thrombosis. The organisms involved were Candida spp. (3), C. Parapsilosis (2), C. albicans (1), C. famata (1), C. lusitanice (1), Staphylococcus spp. (6), and S. aureus (3), as well as the coagulase-negative Staphylococcus (2), alpha hemolytic Streptococcus (1), Diphtheroid bacilli (2), Pseudomonas aeruginosa (2), Ps. Spp. (3), Escherichia coli (3), Klebsiella oxytoca (1), Klebsiella pneumoniae (1), Klebsiella spp. (1), Serratia liquefaciens (1), Serratia fanticola (1), Achromobacter spp. (2) Chromobacterium violaceum (1), Delftia acidovirans (1), Stenotrophomonas maltophile (1), Alcaligenes faecalis (1), and Enterobacter cloacae (1). Two episodes of documented thrombosis were observed. One case presented with right atrial thrombosis/SVC syndrome and the other case presented with left upper arm thrombosis. Two patients died with ports in situ, while five patients had ports in place at the time of this study. The median working life of the ports was 688.5 days (range: 39–3925). The rate of infective complications was 2.63 infections per 1000 catheter days, and the number of infections was significantly correlated with the number of ports [Pearson's r = 0.66; p < 0.01]. Discussion: Our results suggest that patients with SCD suffer infective complications associated with the PORT-A-CATH®, which often necessitate its removal. Although these devices are extremely useful, their optimal beneficial potential is only realized if the patients receive proper care at special centers well-versed in the maintenance of such devices by experienced staff. Keywords: PORT-A-CATH®, Sickle cell disease, Infections, Complications
url http://www.sciencedirect.com/science/article/pii/S1876034111001055
work_keys_str_mv AT salamalkindi complicationsofportacathinpatientswithsicklecelldisease
AT samaamatwani complicationsofportacathinpatientswithsicklecelldisease
AT alghaliaalmaawali complicationsofportacathinpatientswithsicklecelldisease
AT buthainaalmaskari complicationsofportacathinpatientswithsicklecelldisease
AT anilpathare complicationsofportacathinpatientswithsicklecelldisease
_version_ 1724752324859002880